Risk of adverse outcomes from COVID-19 is higher for patients with cancer
1. COVID-19 patients with cancer had increased rates of hospitalization, ICU stay, and mortality than patients without cancer. 2. Patients...
1. COVID-19 patients with cancer had increased rates of hospitalization, ICU stay, and mortality than patients without cancer. 2. Patients...
1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group. 2....
1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free...
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the...
1. Camrelizumab and apatinib treatment provided a 55% objective response rate 2. A complete response was observed in 50% of...
1. Patients receiving Ivosidenib had longer overall survival as compared to patients on placebo. 2. Quality of life measures favored...
1. Patients on adavosertib had both increased progression-free survival and better tumor control, as compared to patients being actively monitored...
1. Progression-free survival was extended by the use capecitabine as compared to active monitoring, but at the expense of increased...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.